SG11201610243YA - Treatment of severe hypertriglyceridemia - Google Patents

Treatment of severe hypertriglyceridemia

Info

Publication number
SG11201610243YA
SG11201610243YA SG11201610243YA SG11201610243YA SG11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA SG 11201610243Y A SG11201610243Y A SG 11201610243YA
Authority
SG
Singapore
Prior art keywords
treatment
severe hypertriglyceridemia
hypertriglyceridemia
severe
Prior art date
Application number
SG11201610243YA
Inventor
Pol Boudes
Yun-Jung Choi
Robert L Martin
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of SG11201610243YA publication Critical patent/SG11201610243YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201610243YA 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia SG11201610243YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
SG11201610243YA true SG11201610243YA (en) 2017-01-27

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610243YA SG11201610243YA (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Country Status (16)

Country Link
US (1) US20150374649A1 (en)
EP (1) EP3160458A1 (en)
JP (1) JP2017519028A (en)
KR (1) KR20170020514A (en)
CN (1) CN106470675A (en)
AU (1) AU2015279905A1 (en)
BR (1) BR112016028918A2 (en)
CA (1) CA2951280A1 (en)
CL (1) CL2016003290A1 (en)
EA (1) EA201790091A1 (en)
HK (1) HK1231380A1 (en)
IL (1) IL249757A0 (en)
MX (1) MX2016017081A (en)
PH (1) PH12016502415A1 (en)
SG (1) SG11201610243YA (en)
WO (1) WO2015200580A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (en) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Treatment of intrahepatic cholestatic diseases
EA036704B1 (en) 2014-04-11 2020-12-10 Саймабэй Терапьютикс, Инк. Method of treating non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019126597A1 (en) * 2017-12-21 2019-06-27 Kowa Company, Ltd. Methods of treatment of hypertrigl yceridemia
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012241B1 (en) 2003-09-19 2009-08-28 Янссен Фармацевтика, Н.В. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs thereof
JO3006B1 (en) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives
WO2011123401A1 (en) * 2010-03-30 2011-10-06 Novartis Ag Uses of dgat1 inhibitors

Also Published As

Publication number Publication date
EA201790091A1 (en) 2017-07-31
CA2951280A1 (en) 2015-12-30
BR112016028918A2 (en) 2017-08-22
PH12016502415A1 (en) 2017-02-27
CN106470675A (en) 2017-03-01
WO2015200580A1 (en) 2015-12-30
IL249757A0 (en) 2017-02-28
AU2015279905A1 (en) 2017-02-02
JP2017519028A (en) 2017-07-13
US20150374649A1 (en) 2015-12-31
CL2016003290A1 (en) 2017-09-08
MX2016017081A (en) 2017-05-01
EP3160458A1 (en) 2017-05-03
HK1231380A1 (en) 2017-12-22
KR20170020514A (en) 2017-02-22

Similar Documents

Publication Publication Date Title
IL259110A (en) Treatment of osteoarthritis
IL252839A0 (en) Treatment of pemphigus
GB201701673D0 (en) Methods of well treatment
FI3851537T3 (en) Treatment of hyperbilirubinemia
SG11201609265RA (en) Characterizing states of subject
IL285003A (en) Treatment of joint conditions
SG11201609652RA (en) Treatment of polybacterials infections
HK1231380A1 (en) Treatment of severe hypertriglyceridemia
HK1244711A1 (en) Treatment of hmgb1-mediated inflammation
GB201410116D0 (en) Method of treatment
GB201416832D0 (en) Methods of treatment
IL253028B (en) Method of treatment
IL246880A0 (en) Treatment of neoplasia
GB201408297D0 (en) Treatment of cancer
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201512139D0 (en) Methods of treatment
GB201417456D0 (en) Treatment of cancer
GB201402298D0 (en) Processing of microalgae
ZA201504639B (en) Treatment of water
PT3851537T (en) Treatment of hyperbilirubinemia
GB201417465D0 (en) Treatment of cancers
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer